Galectin Therapeutics GALT
NASDAQ GALT
$4.67 +0.32 (+7.36%)
As of: Sep 4, 2026 · 2:33 PM EDT

Galectin Therapeutics (GALT) Equity Income (2014)

Analysis

Galectin Therapeutics (GALT) Equity Income (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.51 Bn 77.52 Bn 3.93 Bn -
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn -
4 Moderna 58.20 Bn 53.06 Bn 52.00 Mn -
5 Revolution Medicines 44.04 Bn 44.04 Bn - -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn -
8 Royalty Pharma 28.40 Bn 27.56 Bn - 4.08 Mn
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -
10 Galectin Therapeutics 308.29 Mn 308.29 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 -10,000.00
Sep 30, 2014 -53,000.00
Jun 30, 2014 -67,000.00
Mar 31, 2014 -270,000.00